Candice Church

Title: Candice Church: Innovator in Cancer Research

Introduction

Candice Church is a prominent inventor based in Seattle, WA, known for her significant contributions to cancer research. She has developed innovative solutions aimed at improving treatment options for patients suffering from Merkel cell carcinoma. Her work is characterized by a strong focus on high-affinity T cell receptors that target specific cancer antigens.

Latest Patents

Candice Church holds a patent titled "High affinity Merkel cell polyomavirus T antigen-specific TCRs and uses thereof." This patent provides binding proteins and T cell receptors (TCRs) that exhibit high affinity and specificity against Merkel cell polyomavirus T antigen epitopes. The technology includes T cells expressing these high-affinity TCRs, nucleic acids encoding them, and compositions designed for treating Merkel cell carcinoma. She has 1 patent to her name.

Career Highlights

Throughout her career, Candice has worked with esteemed institutions such as the Fred Hutchinson Cancer Center and the University of Washington. Her research has been pivotal in advancing the understanding of Merkel cell carcinoma and developing targeted therapies.

Collaborations

Candice has collaborated with notable colleagues in her field, including Aude Georgiana Chapuis and Paul T Nghiem. These partnerships have enhanced her research efforts and contributed to the advancement of cancer treatment methodologies.

Conclusion

Candice Church is a dedicated inventor whose work in cancer research has the potential to significantly impact patient care. Her innovative approaches to targeting cancer antigens exemplify the importance of research in developing effective therapies.